, /PRNewswire/ -- Since last year, Memory Treatment Centers (MTC) has been a providing hundreds of patients with the first-ever proactive approach to treating and preventing progression of the disease. Now, MTC continues to innovate in neurocognitive care by giving Alzheimer's disease (AD) patients additional treatment options. Through , MTC is now offering access to the recently FDA-approved therapy, Kisunla (donanemab).
encouraged Dr. of Memory Treatment Centers Jacksonville. On , the of , marking the start of a new class of drugs designed to tackle beta-amyloid buildup in those with AD.
The FDA was expected to decide in March but delayed approval to gain more insight from the advisory panel about potential side effects. The treatment is associated with amyloid related imaging abnormalities (ARIA) which is a consequence of plaques being removed. The FDA advisory panel voted unanimously on the efficacy of Kisunla for the treatment of early AD.
While ARIA-related side effects were observed in a minority of patients, serious complications occurred in only 1.6% of people. With Alzheimer's leading to reliance on caregivers, eventual fatality, , the ability to target a root cause of cognitive decline vastly outweighed the risk of side effects.
MTC has reported no issues thus far in administering The clinical team understands the risks of ARIA and is working tirelessly to ensure patient safety. Clinics are using the most up to date imaging techniques and indicators, such as , to a.